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To test whether quantitative gait analysis of gait under single- and dual-task conditions can be
used for a differential diagnosis of progressive supranuclear palsy (PSP) and idiopathic normal-
pressure hydrocephalus (iNPH).
Methods
In this cross-sectional study, temporal and spatial gait parameters were analyzed in 38 patients
with PSP (Neurological Disorders and Stroke and Society for Progressive Supranuclear Palsy
diagnostic criteria), 27 patients with iNPH (international iNPH guidelines), and 38 healthy
controls. A pressure-sensitive carpet was used to examine gait under 5 conditions: single task
(preferred, slow, and maximal speed), cognitive dual task (walking with serial 7 subtractions),
and motor dual task (walking while carrying a tray).
Results
The main results were as follows. First, both patients with PSP and those with iNPH exhibited
significant gait dysfunction, which was worse in patients with iNPH with a more broad-based
gait (p < 0.001). Second, stride time variability was increased in both patient groups, more
pronounced in PSP (p = 0.009). Third, cognitive dual task led to a greater reduction of gait
velocity in PSP (PSP 34.4% vs iNPH 16.9%, p = 0.002). Motor dual task revealed a dissociation
of gait performance: patients with PSP considerably worsened, but patients with iNPH tended
to improve.
Conclusion
Patients with PSP seem to be more sensitive to dual-task perturbations than patients with
iNPH. An increased step width and anisotropy of the effect of dual-task conditions (cognitive vs
motor) seem to be good diagnostic tools for iNPH.
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Progressive supranuclear palsy (PSP) and idiopathic normal-
pressure hydrocephalus (iNPH) have in common that they
are clinically characterized by gait dysfunction, postural in-
stability with retropulsion, and cognitive impairment. More-
over, they seem to share common pathophysiologic
mechanisms, with dysfunction of the frontal lobe–basal
ganglia and thalamo-mesencephalic loops.1–6
There are accepted diagnostic criteria for PSP and iNPH.
However, autopsy studies have demonstrated that the differ-
ential diagnosis of both disorders during lifetime might be
difficult, not just early in the course of the disease.7–9
The 2 disorders have certain differences in gait. Gait in PSP is
characterized by the tendency to fling the legs forward and
turn around abruptly without appropriate control.3,10 In
contrast, gait in iNPH is broad based, the feet appear glued to
the ground, and arm swing is exaggerated in at least some
cases.3,11 While patients with PSP fall more frequently than
patients with iNPH, the falls in both disorders are most likely
related to motor and cognitive impairments.12 Gait perfor-
mance under dual-task conditions critically depends on intact
frontal lobe–basal ganglia locomotion loops.13 So far, gait
performance during cognitive and motor dual tasks has not
been specifically addressed in studies of PSP, and quantitative
gait parameters of PSP and iNPH have not been compared
despite their clinical similarities.
The aims of the present study were to directly compare gait
performance in patients with PSP and those with iNPH under
single- and dual-task conditions, to test whether quantitative
gait analysis can be used for a differential diagnosis of PSP and
iNPH, and to stimulate the scientific discussion on the un-
derlying pathophysiology of gait disorders in PSP and iNPH.
Methods
Participants
Thirty-eight patients with PSP and 27 patients with iNPH,
diagnosed at the Department of Neurology, Ludwig-
Maximilians University Munich, were recruited for this pro-
spective cross-sectional study. The diagnosis of PSPwas based
on the criteria of the National Institute for Neurological
Disorders and Stroke and Society for Progressive Supra-
nuclear Palsy.14 The diagnosis of iNPH was based on the
international iNPH guidelines.2 Patients with iNPH were
evaluated before CSF drainage. Each patient with PSP was age
and sex matched to a healthy control (HS) with no history of
neurologic or orthopedic problems that could affect gait and
postural control. All participants underwent a complete
neurologic and neuro-ophthalmologic examination. The
complete CERAD-Plus (Consortium to Establish a Registry
for Alzheimer’s Disease) neuropsychological test battery and
tonic (mean time iNPH 346 ± 87 milliseconds) and phasic
alertness (mean time iNPH 329 ± 82 milliseconds) were
measured in the patients with iNPH. The Mini-Mental State
Examination and Frontal Assessment Battery (mean PSP
13.9 ± 2.3) were performed in the patients with PSP. Partic-
ipants were not explicitly matched according to those meas-
ures. Additional technical diagnostic procedures were
performed (e.g., electrophysiologic examination, MRI of the
spinal cord, and vestibular testing) to exclude differential
diagnoses and neurologic comorbidities relevant for gait and
cognitive function. All participating patients were able to walk
at least 10 m without a walking aid.
Standard protocol approvals, registrations,
and patient consents
The study was performed in accordance with the 1964 Dec-
laration of Helsinki and was approved by the local ethics
committee. Written informed consent was obtained from all
participants.
Clinical assessment
The PSP Rating Scale was assessed at the time of examina-
tion.15 Every patient included in this study performed the
Functional Gait Assessment in addition to the gait analysis.16
This score did not differ between the 2 patient groups (PSP
18.5 ± 4.0 vs iNPH 18.8 ± 3.7, p = 0.68), and an in-
terindividual comparison showed a good match. Thus, the
differences in gait performance could not be explained by
differences in the severity of the gait disorder in general. An
evaluation of falls within the last 6 months was made for each
patient.17 The midbrain diameter and the Evan index (maxi-
mal width of frontal horns/maximal width of inner skull) were
quantitatively measured by MRI. The Fazekas scale was used
to quantify the amount of white matter T2-hyperintense
lesions.18 To exclude patients with a differential diagnosis or
comorbidities, only patients scoring <2 on the Fazekas scale
were included.
Gait assessment
Gait was analyzed with a computer-based, 6.7-m-long
pressure-sensitive carpet system (GAITRite, CIR System,
Havertown, PA) with a sampling rate of 120 Hz. Relevant
temporal and spatial gait cycle parameters were recorded.
The gait analysis involved a protocol of 5 different conditions:
3 single-task conditions (preferred, slow, and maximal
speed), 1 cognitive dual-task condition (serial 7 subtractions
from 100), and 1 motor dual-task condition (carrying a tray).
Each condition was tested twice. To ensure steady-state
Glossary
CERAD = Consortium to Establish a Registry for Alzheimer’s Disease; CV = coefficient of variation; HS = healthy controls;
iNPH = idiopathic normal-pressure hydrocephalus; PD = Parkinson disease; PSP = progressive supranuclear palsy.
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locomotion, every walk was started 1.5 m in front of the carpet
and continued for 1.5 m behind it. The use of assistive
walking aids was not allowed. Patients were always safe-
guarded by a researcher walking alongside. For the single-
task conditions, the instructions were as follows: to walk
with preferred velocity, slowly, and as fast as possible, but
without running, and still safely. As dual-task conditions, the
patients walked at their preferred speed while simulta-
neously counting backward or carrying a tray. No prioriti-
zation of any task was required. The researcher continuously
motivated the participant to keep on calculating and walking
to avoid any prioritization.
Statistical analysis
The primary outcome measures were velocity (centimeters
per second), cadence (steps per minute), step width (centi-
meters), stride length (centimeters), and coefficient of vari-
ation (CV)19 of stride time, stride length, and step width.
CVð%Þ = SD  of   parameter × 100
mean  of   parameter
The CV of stride length represents the variability in the
anterior-posterior plane. The CV of step width represents the
variability in the mediolateral plane.
Dual-task costs express the effect of divided attention and
were presented as the percentage of the difference between
single task and dual task.11 Dual-task costs were calculated for
all primary outcome measures.
Dual  task   costð%Þ
=
parameter  under  dual  task − parameter  under  single  task
parameter   under  single  task
× 100
Statistical analyses were performed with SPSS (Statistical
Package for Social Sciences, version 23, SPSS, Inc, Chicago,
IL). For categorical data, absolute (number) and relative
(percent) frequencies were determined and compared by use
of the χ2 test. Continuous data were presented as mean values
with the corresponding SDs. The Kolmogorov-Smirnov test
was used to ascertain whether data were normally distributed.
Paired and unpaired t tests were used to compare normally
distributed data. The effects of the dependent variable were
analyzed with a 1-way analysis of variance. To address the
question of the added value of dual-task testing in the
differential diagnosis of PSP and iNPH, we performed dis-
criminant analysis using gait parameters as independent var-
iables and the patient groups (HS, PSP, iNPH) as dependent
variables. The gait parameters of the 3 gait conditions (single
task, cognitive dual task, motor dual task) were used sepa-
rately and in combination to build a predictive model for
group membership. The results were considered significant
at p < 0.05.
Results
Patient characteristics
Mean age and sex distribution did not significantly differ
between the 3 groups (table 1). First and leading symp-
toms of patients with PSP were generalized bradykinesia,
Table 1 Single-task gait parameters in HS and patients with PSP and iNPH
HS (n = 38), mean (SD) PSP (n = 38), mean (SD) iNPH (n = 27), mean (SD)
p Value
HS vs PSP HS vs iNPH PSP vs iNPH
Female sex, n (%) 18 (47) 18 (47) 6 (22) 0.82 0.056 0.056
Age, y 68.9 (7.6) 69.0 (6.3) 72.0 (8.1) 0.95 0.12 0.11
Preferred speed
Velocity, cm/s 111.6 (22.5) 82.3 (24.0) 63.9 (15.9) <0.001 <0.001 0.001
Cadence, steps/min 108.5 (12.5) 98.3 (17.9) 98.3 (13.3) <0.001 <0.001 0.99
Stride length, cm 122.9 (15.2) 99.0 (17.6) 78.3 (16.3) <0.001 <0.001 <0.001
Step width, cm 9.3 (3.2) 10.2 (5.5) 16.0 (3.3) 0.41 <0.001 <0.001
CV of stride time, % 2.4 (1.0) 5.5 (3.7) 3.8 (1.2) <0.001 <0.001 0.009
CV of stride length, % 2.9 (1.4) 5.2 (3.3) 6.8 (3.6) <0.001 <0.001 0.063
CV of step width, % 23.4 (10.6) 10.2 (67.8) 12.8 (5.2) 0.24 <0.001 0.84
Slow speed
Velocity, cm/s 59.9 (21.7) 42.6 (16.0) 35.9 (8.9) <0.001 <0.001 0.055
Maximal speed
Velocity, cm/s 159.7 (25.3) 125.9 (28.8) 106.9 (21.4) 0.001 0.001 0.005
Abbreviations: CV = coefficient of variability; HS = healthy controls; iNPH = idiopathic normal-pressure hydrocephalus; PSP = progressive supranuclear palsy.
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gait disturbance with falls, and supranuclear vertical gaze
palsy (PSP Rating Scale score 31.1 ± 8.9). MRI scans of the
brain showed relevant midbrain atrophy (mean midbrain
diameter 15 ± 2 mm). The leading symptoms of patients
with iNPH were gait dysfunction with slow, broad-based,
and small-stepped gait, as well as cognitive deficits. The
Evan index, an established parameter of ventricular en-
largement,2 was increased by 0.40 ± 0.05 in the iNPH
group. The duration of symptoms was longer in the PSP
group (PSP 42.1 ± 27.5 vs iNPH 23.4 ± 19.9 months, p =
0.009). The rate of falls within the past 6 months
was higher in the patients with PSP (PSP 100% vs iNPH
56%, p < 0.001).
Single-task condition
Compared to HS, both patients with PSP and those with
iNPH had a significantly inferior gait performance (table 1).
Compared with patients with PSP, the gait of patients with
Figure 1Medians, 25% and 75% percentiles, andminimal andmaximal values for single- and dual-task gait parameters in
HS and patients with PSP and iNPH
The gait of patients with iNPH was characterized by a (A) lower velocity (p = 0.001) and (B) stride length (p < 0.001) than in patients with PSP. The main
differences were (C) a more broad-based gait in iNPH (p < 0.001) and (D) a higher CV of stride time in patients with PSP than in those with iNPH (p = 0.009).
Under the cognitive dual-task condition (serial 7 subtractions from 100), gait velocity was clearly more reduced in patients with PSP, while the reduction in
patientswith iNPHwas comparable to that inHS (velocity reductions: PSP 34.4%, iNPH16.9%, HS 14.8%). Under themotor dual-task condition (carrying a tray),
velocity decreased in PSP by 10.3%; in contrast, velocity increased by 7.0% in patients with iNPH. CV = coefficient of variation; HS = healthy controls;
iNPH = idiopathic normal-pressure hydrocephalus; PSP = progressive supranuclear palsy.
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iNPH was characterized by a lower velocity (p = 0.001) and
shorter stride length (p < 0.001). The main differences were
a more broad-based gait in iNPH (p < 0.001) and a higher CV
of stride time in PSP (p = 0.009) (figure 1).
When expressed as a function of gait velocity, the CV of stride
time was highest for slow velocity and lowest for maximal
velocity in both patient groups (figure 2). In patients with
PSP, the CV of stride length increased at the time when the
CV of step width decreased (Spearman rank correlation co-
efficient = −0.338). This correlation was not seen in patients
with iNPH or HS.
Cognitive dual-task condition
As a general index of cognitive functioning, the Mini-Mental
State Examination was compared between both groups (mean
score: PSP 27.3 ± 3.1 vs iNPH 23.4 ± 3.3, p = 0.001). The
phonemic verbal fluency was compared between both groups
to determine frontal-executive functioning (mean number:
PSP 9.7 ± 4.5 vs iNPH 9.1 ± 4.0 words, p = 0.661). Cognitive
dual task led to a significant impairment of gait in all 3 groups.
Patients with PSP were significantly more sensitive to
dual-task perturbation than patients with iNPH (table 2).
Especially gait velocity was clearly more reduced in patients
with PSP, while the reduction in patients with iNPH was
comparable to that in HS (figure 1).
Motor dual-task condition
Motor dual task led to a significant decrease of gait velocity
and stride length in patients with PSP, but to a lesser extent
than cognitive dual task (table 2). These effects were also
significant compared to those in HS and patients with iNPH.
Surprisingly, the gait performance of patients with iNPH
tended to even improve in the motor dual task (p = 0.17). For
example, while the most relevant parameter, gait velocity,
decreased in patients with PSP, it increased in patients with
iNPH (figure 1).
Discriminant analysis
The gait parameters from the single-task condition were
found to be able to classify patients into the 3 groups (PSP,
iNPH, HS) with an accuracy of 76.7% (Wilks Λ = 0.298,
p < 0.001). For the cognitive dual task, the accuracy was 77.7%
(Wilks Λ = 0.292, p < 0.001), and for the motor dual task, the
accuracy was 76.7% (Wilks Λ = 0.290, p < 0.001). When the
gait parameters of all 3 conditions were combined, 90.3% of
the patients were correctly classified (Wilks Λ = 0.130,
p < 0.001).
The accuracy for the differential diagnosis of only PSP and
iNPH (without HS) in the single task was 81.5% (Wilks Λ =
0.559, p < 0.001), in the cognitive dual task was 83.1% (Wilks
Λ = 0.557, p < 0.001), in the motor dual-task was 86.2%
Figure 2 Stride time variability depends on gait velocity
Individual values for slow, preferred, and maximal walking
speed. Loess curve fitting was used to visualize the data.
Both patient groups showed abnormally high CV of stride
time; it was most prominent during slow walking speed.
CV = coefficient of variation; HS = healthy controls (dotted
line); iNPH = idiopathic normal-pressure hydrocephalus
(continuous line); PSP = progressive supranuclear palsy
(broken line).
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(Wilks Λ = 0.510, p < 0.001), and in the combination of all 3
conditions was 96.9% (Wilks Λ = 0.264, p < 0.001).
Discussion
The main findings of this study can be summarized as follows:
compared with patients with PSP, the gait of patients with
iNPH was slower and more broad based; gait variability was
higher in patients with PSP; and patients with PSP were more
sensitive to dual-task perturbation. Under motor dual task,
patients with iNPH tended to even improve.
Our patient groups showed a few typical gait changes re-
garding the gait parameters. The gait of patients with iNPH
was slower and more broad based than that of patients with
PSP, although the symptoms of patients with iNPH were of
shorter duration. Similar results were reported by 2 previous
studies that compared gait parameters in patients with iNPH
and patients with Parkinson disease (PD).20,21 The slower
gait speed in iNPH might reflect a more specific impairment
of the cerebral locomotion network compared to that in PSP
or PD. The anatomic correlate might be the medial septum
neurons in the frontal lobe, which animal studies have shown
mediate locomotion speed.22,23 This area is often affected by
periventricular gliosis in iNPH. An alternative interpretation
might be that the course of disease progression in iNPH is
steeper. However, our data and that of other studies20,21
cannot really differentiate disease progression or a longer
asymptomatic phase. The broad-based gait in iNPH has been
shown in the past to be a very promising parameter for dif-
ferential diagnosis with PD.21 The PSP data on step width are
controversial.10,24 HS also exhibit an iNPH-like gait pattern,
but only in situations associated with fear of falls.3 One might
assume that patients with iNPH value stability over efficiency.
Gait variability as a marker for fall risk was higher in patients
with PSP.25–27 This correlates well with clinical observations
that the risk of falls increases in both iNPH and PSP, but more
so in PSP. We found that the variability of stride duration
decreased with increased walking speed in both patient
groups. This effect was more pronounced in PSP. This might
be due to an upregulation of the so-called direct locomotion
pathway in PSP to compensate for the malfunctioning of the
indirect locomotion pathways, as discussed elsewhere.4
In the discriminant analysis, the single task alone already yielded
good accuracy in the differential diagnosis of PSP, iNPH, and
HS.Nevertheless, the addition of the dual-task conditions led to
a considerable increase of accuracy (13.6%). The results of the
discriminant analysis demonstrate that quantitative gait analysis
can be used for a differential diagnosis of PSP and iNPH.
Table 2 Dual-task costs in HS and patients with PSP and iNPH
HS (n = 38), mean (SD) PSP (n = 38), mean (SD) iNPH (n = 27), mean (SD)
p Value
HS vs PSP HS vs iNPH PSP vs iNPH
Cognitive dual-task
cost
Velocity, % −14.8 (14.8)a −34.4 (19.0)a −16.9 (25.4)a <0.001 0.70 0.002
Cadence, % −9.0 (10.3)a −17.6 (13.9)a −5.1 (12.7)a 0.003 0.18 <0.001
Stride length, % −7.0 (9.2)a −22.0 (13.1)a −13.6 (17.0)a <0.001 0.075 0.028
Step width, % 7.4 (25)a 19.6 (50.5)a 15.9 (17.3)a 0.19 0.13 0.72
CV of stride time, % 100.6 (157.8)a 182.7 (282.9)a 251.0 (292.6)a 0.20 0.020 0.26
CV of stride length, % 43.2 (85.0)a 138.5 (200.0)a 110.1 (138.2)a 0.008 0.031 0.53
CV of step width, % 3.1 (57.4) −52.5 (202.8) −14.1 (33.5)a 0.11 0.16 0.34
Motor dual-task cost
Velocity, % 4.0 (15.1) −10.3 (15.3)a 7.0 (18.1) <0.001 0.50 <0.001
Cadence, % 4.6 (8.2)a −1.7 (9.6) 3.2 (8.2) 0.003 0.50 0.036
Stride length, % −0.8 (7.4) −8.8 (10.7)a 2.9 (13.6) <0.001 0.16 <0.001
Step width, % −0.0003 (16.9) 2.8 (46.4) −0.37 (10.7) 0.73 0.92 0.69
CV of stride time, % 34.0 (198.8) 22.3 (80.4) −6.0 (31.9) 0.74 0.92 0.056
CV of stride length, % −3.9 (57.0)a 24.3 (104.6) 20.8 (47.7) 0.15 0.071 0.87
CV of step width, % 8.1 (54.4) 20.1 (158.5) 0.3 (42.9) 0.66 0.54 0.53
Abbreviations: CV = coefficient of variability; HS = healthy controls; iNPH = idiopathic normal-pressure hydrocephalus; PSP = progressive supranuclear palsy.
a Significantly different from the single-task condition within group.
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Moreover, it is worthwhile to perform dual-task testing in ad-
dition to single-task testing. An earlier study of patients with
PSP found that a cognitive dual-task condition could be used to
discriminate patients according to their fall risk.13 We showed
that a cognitive dual-task increases variability in the anterior-
posterior plane and decreases gait velocity in PSP and iNPH,
more pronounced in patients with PSP. One might consider
this to be a floor effect, given the already slow gait velocity at
baseline in patients with iNPH. However, when specifically
instructed to walk slowly, patients with iNPH demonstrated
that they were capable of further reducing their velocity (slow
speed velocity 35.9 cm/s, cognitive dual-task velocity 53.0 cm/
s, motor dual-task velocity 66.9 cm/s). That patients with PSP
are more sensitive to dual-task perturbation at first seems to be
exactly the opposite of what is initially expected because the gait
of patients with PSP is considered subcortical and hypokinetic,
while that of patients with iNPH is a frontal gait type.20 In this
study, participants were not matched for their cognitive func-
tion, but the phonemic verbal fluency, an index of frontal-
executive functioning, did not show any difference between the
2 patient groups.28,29 Thus, their different performance during
the cognitive dual task is not explained by differences in cog-
nitive impairment. The inferior performance of patients with
PSP therefore might indicate that more cortical, especially
prefrontal, control is already necessary for single-task gait so
that their capacities for additional recruitment are saturated.
They also might have a reduced capacity per se for cortical and
prefrontal recruitment.30 The results in the discriminant anal-
ysis showed that the motor dual task was the most exact con-
dition for differentiating PSP and iNPH. The gait performance
of patients with iNPH and those with PSP showed a surprising
dissociation during this condition. As expected, gait in patients
with PSP worsened during motor dual task (although not as
much as during cognitive dual task). In contrast, patients with
iNPH tended to even improve. One interpretation might be
that the motor dual task was not challenging enough for the
iNPH group. In future studies, it would be interesting to in-
crease the task complexity (i.e., by adding a glass filled with
water) to test whether the improvement trend observed here
becomes significant. However, because the patients with PSP
already had major difficulties with this motor dual task, an
increase in task complexity was not possible in our study. We
hypothesize that dual-task situations result in increased activity
of the prefrontal cortex, which partly compensates for the loss
of callosal interhemispheric connections in iNPH. Because the
motor dual task was the last condition tested in all the patients,
a learning effect cannot be excluded.However, this seems rather
unlikely because a tendency to improve was not observed in the
PSP group or in other cohorts tested with the same paradigm in
the past.11,19,31 Together, these interactions support the view
that cognition and locomotion share common prefrontal areas
and that the improvement of cognitive functions plays an es-
sential role in the rehabilitation of gait disorders and vice
versa.30 There was a correlation, with the CV of stride length
increasing at the time when the CV of step width decreased, in
patients with PSP that was not seen in patients with iNPH or in
HS.Mediolateral and anterior-posterior gait aspects in PSP thus
seem to be closely connected with each other.24,32 Interesting
questions for future physical therapy studies are the medio-
lateral gait aspects of PSP and whether balance training in PSP
and iNPH should focus on slow speed.
Our study has certain limitations. The most important one is
the absence of a histopathologic diagnosis. This is a limitation of
every study that relies on a clinical diagnosis. Because we were
aware of this problem, we included only typical clinical cases
that were examined and characterized in detail. A second un-
avoidable limitation of studies that compare different diseases is
the definition of symptom load. We tried to solve this problem
by determining the Functional Gait Assessment. We did not
explicitly pose the question of whether the patients prioritized 1
task (calculation task vs walking task) because we did not ex-
amine the single-task calculation while the patient was seated.
The new and clinically relevant findings reported in this study
are that patients with PSP are more sensitive to dual-task per-
turbations than patients with iNPH. The increased step width
and anisotropy of the effect of dual-task conditions (cognitive vs
motor) appear to be good diagnostic criteria for iNPH. The
high rate of correct classification in the discriminant analysis
reflects the high quality of our data and shows that quantitative
gait analysis allows a differential diagnosis of PSP and iNPH.
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Gait analysis in PSP and NPH
Dual-task conditions make the difference
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Can quantitative gait analysis under single- and dual-task
conditions provide a differential diagnosis between progressive
supranuclear palsy (PSP) and idiopathic normal pressure
hydrocephalus (iNPH)?
Summary answer
Quantitative gait analysis under dual-task conditions can
provide such a differential diagnosis.
What is known and what this paper adds
PSP and iNPH are both characterized by gait dysfunction,
postural instability, and cognitive impairment, but they differ
in the precise nature of the gait dysfunction. This study
provides evidence that these differences can be utilized to
achieve a differential diagnosis under appropriate gait anal-
ysis conditions.
Participants and setting
This study recruited 38 patients with PSP and 27 patients with
iNPH through the Ludwig-Maximilians University of Munich
Department of Neurology. The diagnoses were based on
standard international guidelines. All participants could walk
unassisted for at least 10 m.
Design, size, and duration
The participants underwent basic neurologic and general clini-
cal assessments, including general gait assessments to confirm
between-group equivalence in general gait disorder severity.
The participants underwent quantitative gait analysis under 3
different single-task conditions (i.e., walking at different speeds),
a cognitive dual-task condition (i.e., walking while counting
backwards), and a motor dual-task condition (i.e., walking while
carrying a tray). Gait measures such as velocity, cadence, step
width, and stride length were automatically captured.
Main results and the role of chance
Cognitive dual-task led to a greater reduction of gait velocity in
PSP (PSP: 34.4% vs. iNPH: 16.9%; p = 0.002). Motor dual-task
revealed a dissociation of gait performance: PSP patients con-
siderably worsened, but iNPH patients tended to improve. By
combining the gait measurements from the single-task and dual-
task conditions patients could be classified into PSP and iNPH
groups with 96.9% accuracy (Wilks’s Λ, 0.264; p < 0.001).
Bias, confounding, and other reasons
for caution
The study did not obtain histopathologic confirmation of
diagnoses. Between-group comparisons were potentially
complicated by differing definitions of symptom loads. The
study also did not address whether the participants prioritized
one task over the other under the dual-task conditions.
Generalizability to other populations
The study exclusively examined patients with typical cases.
This may limit generalizability to atypical cases.
Study funding/potential competing interests
This study was funded by the German government. The











Velocity 0.001 0.002 <0.001
Cadence 0.99 <0.001 0.036
Stride length <0.001 0.028 <0.001
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